Because of the severe toxicity of systemically applied tumor necrosis factor (TNF) in cancer patients, considerable efforts have been made t o construct mutant TNF molecules, which retain antitumor activity, but display less toxicity. We compared tumor suppression in relation t o the toxic effects of human TNF and human lymphotoxin (LT) in mice. The genes for these two cytokines were expressed in Chinese hamster ovary (CHO) cells. Intraperitoneal injection of parental and gene modified CH0 cell lines producing similar amounts of biologically active TNF or LT, respectively, into nude mice showed that CHO-TNF cells killed the mice more rapidly than parental cells, but that CHO-LT tumor bearing mice lived significantly longer than mice injected with parental cells.
UMOR NECROSIS FACTOR (TNF) has multiple effects in vivo including immunologically mediated tumor growth inhibition, hemorrhagic necrosis, cachexia, and septic shock.'.' It has been widely used to treat cancer patients, but seemingly the high toxicity of systemic TNF did not allow application of sufficient amounts of TNF to obtain curative effects in most Experiments with tumor cells transfected to produce TNF have shown that low amounts of TNF secretion could induce an antitumor response, which led to rejection of the tumor in the absence of any toxi~ity.~.~ In other models, despite tumor growth inhibition, TNF secreted by gene modified tumor cells, induced cachexia or wasting of the Although the reason for this discrepancy is poorly understood, the amount of secreted TNF and/or the particular tumor, which has been used, may contribute to toxicity. It was shown that TNFmediated toxicity requires the synergistic action of other factors, such as bacterial polysaccharide or noncharacterized tumor cell components.'0," Oliff et al' reported that, depending on the injection site in nude mice, TNF producing Chinese hamster ovary (CHO) cells either grew much slower as tumor than parental cells (subcutaneous injection), induced cachexia (intramuscular), or killed the mice faster in comparison with parental cells (intraperitoneal). As shown in another model with a TNF gene transfected tumor, cachexia developed only when certain TNF serum levels (250 to 500 pg/mL human TNF) were reached.' The different effects induced by CHO-TNF cells in nude mice required different injection sites. However, as shown here, subcutaneous injection of the cells into severe combined immunodeficiency (SCID) mice allowed direct analyses of the wanted and unwanted effects of TNF and comparison of lymphotoxin (LT) and TNF with respect to both effects.
Due to the high-toxicity observed on treatment of cancer patients with TNF, efforts have been made to separate the beneficial and the deleterious activities of TNF. For instance, mutant human TNF molecules have been selected, which lost the binding ability to one of the TNF receptors (TNF-R2, p75/80), but not to the other (TNF-R1, p55/60). These at least as effective as TNF. However, mice bearing CHO-TNF cells either died rapidly or developed cachexia, as shown by weight loss. In contrast, mice injected with CWO-LT cells never rapidly died and became cachectic much later than CHO-TNF cell injected animals, though serum levels of LT were higher than those of TNF. Analysis of soluble forms of TNF receptors (TNF-R1 and TNF-R21 in sera of tumor bearing mice showed that soluble TNF-R1 was downrsgulated in both CHO-TNF and CHO-LT, in comparison with CHO-neo cell injected mice and t o normal SCID mice. The soluble form of TNF-R2 was induced by CH0 cell lines. In CHO-TNF cell injected SCID mice, serum levels were significantly increased, whereas in mice injected with CHO-LT cells, serum levels of soluble TNF-R2 were decreased. Together, our results show a higher therapeutic index of LT compared with TNF.
0 1995 by The American Society of Hematology.
mutant TNF molecules were shown to mediate the direct cytotoxic effect on some tumor cells and might have less systemic toxicity."
Little has been reported about the tumor suppressive activity of LT, presumably because of its similarities to TNF. Most likely arisen by duplication of an ancestral TNFLT precursor, both genes are adjacently located in the major histocompatibility complex (MHC) locus and are structurally and functionally related.13 There is increasing evidence showing both quantitative and qualitative differences between the function of TNF and LT.I4 For example, Oster et all5 showed that TNF, but not LT, induced secretion of macrophage colony-stimulating factor by human monocytes and more recently, it was demonstrated that LT, but not TNF, acts as an autocrine growth factor for Epstein-Barr virus-infected cells.I6 To compare biologic effects of TNF and LT in vivo, we expressed both cytokine genes in tumor cells. The results showed that both molecules have similar antitumor activity, but that LT is less toxic than TNF.
2780
CCL6I) and grown in RPM1 1640 medium supplemented with 10% fetal calf serum, penicillin, and streptomycin. The TNF and LT gene transfected C H 0 sublines, CHO-TNF.2 and CHO-LT.2, were tested for a variety of infectious agents. Contamination of Lactic dehydrogenase (LDH) virus was excluded by an assay for LDH activity (Monotest; Boehringer Mannheim, Penzburg, Germany; Diagnostics). Cells at an approximate concentration of 5 X lO'/mL were frozen twice and thawed in their conditioned media, and 450 pL of the cell lysate was injected into 3-week-old viral antibody-free NMRI mice and 30 pL was injected intracerebrally into the same mice. Four days postinjection, plasma was obtained from three mice and tested for LDH activity. The following antigens were tested by mouse antibody production test: Hantaanvirus, Lymphocytic choriomeningitis virus (LCM), Reovirus type 3 (reo3), Sendaivirus, Polyomavirus, Ectromeliavirus, Mouse rotavirus (EDIM), K virus (K), Minute virus of mice (MVM), Mouse adenovirus (MAd), Theiler's murine encephalomyelitis virus (TMEV), Mouse hepatitis virus (MHV), Pneumonia virus of mice (PVM), Mouse cytomegalovirus (MCMV), Mouse thymic virus (MTV) and Mycoplasma pulmonis. Cell lysates as described above were injected at 450 pL intraperitoneally and 50 pL oronasally into antigen-negative NMRl mice (six per group) or 450 pL intraperitoneally and 30 pL intracerebrally (three mice per group). At day 30 postinfection, mice were bled and sera were tested for the above mentioned antigens by an indirect immunofluorescence assay, except for K virus, which was tested by hemagglutination inhibition test. All mouse antibody production tests were kindly performed by V. Kraft, (Biomedical Diagnostics, Hannover, Germany). Mycoplasma infection was also analyzed by enzyme-linked immunosorbent assay (ELISA) (#1296744, Boehringer Mannheim). Both, CHO-TNF.2 and CH0.LT.2 cells were negative for all tested infectious agents.
Plasmid construction and transfection.
Human LT and TNF cDNAs were isolated through reverse polymerase chain reaction (PCR) using primers that contained translation start or stop signals, as well as an additional BamHI recognition site to facilitate cloning (primers for T N F 5'-TCG GAT CCG GAA AGG ACA CCA TGA GCA CT-3' and 5'-AAG GAT CCA TGT TCG TCC TCC TCA CAG G-3'; primers for LT: 5'-TTG GAT CCC CCC ATG ACA CTA CAG AGC G-3'). Extraction of total RNA from a CD4' Tcell clone, which was isolated from the synovial fluid of a rheumatoid arthritis patient (kindly provided by J. Sieper, Berlin), reverse transcription of mRNA into cDNA and PCR were done as described." The expression vector pBA derived from pBAneoIR and pLTR derived from pAptag-l" have been described." The PCR-amplified 0.65 kb LT or 0.74 kb TNF cDNA fragments were cut with BamHl and cloned into the BamHI site of vector pBA, resulting in plasmids pBA-hLT and pBA-hTNF and into the BglII site of vector pLTR resulting in plasmids pLTR-hLT and pLTR-hTNF. The recombinant plasmids pBA-hLT, pBA-hTNF (TNFILT genes controlled by beta actin promoter), and pLTR-hLT, pLTR-hTNF (TNFILT genes controlled by the Moloney Murine Leukemia Virus long terminal repeat (MoMuLV-LTR) promoter) were cotransfected with the neomycin gene containing plasmid pWL-neo in a 1O:l molar ratio into CH0 cells by electroporation using a Gene-Pulser (Bio-Rad Laboratories, Richmond, CA). A total of 2 X lo6 cells in 0.8 mL CaZi, Mg2'-free Dulbecco's phosphate-buffered saline (D-PBS) were pulsed in a 0.4 cm cuvette with 1,500 V, 25 microfarad. The transfected cells were selected in medium containing 0.6 mg/mL G418 and subsequently cloned by limiting dilution.
TNF/LT assay. Bioactivity of TNFLT was determined by the L929 cytotoxicity assay as described? Briefly, L929 cells were plated in 100 pL per well at a density of 3 X lo5 cells/mL in 96 well flat-bottomed plates (Costar, Cambridge, MA) and cultivated for 24 hours. The supernatants were discarded and replaced by I O CCA CCT GAA CGT-3' and 5"TCT GGG ATC CTC CAA GTT pL of 20 pg/mL actinomycin D (Sigma, Deisenhofen, Germany) and 100 pL of culture medium (supernatant of 5 X 10' cells/mL cultured for 48 hours) or TNF standard. After a 20-hour incubation, viable L929 cells were stained with 50 pL of a solution (0.5% crystal violet, 8% formaldehyde, 0.17% NaCI, 22.3% ethanol in bidistilled water) for 15 minutes at room temperature. After an intensive wash with tap water, plates were dried, the cells were redisolved in IO0 pL of 33% acetic acid and 1% Triton X-l00 (Serva, Heidelberg, Germany) in bidistilled water and absorption at 595 nm was measured by a Titertek ELISA reader. Recombinant murine TNF (B1243; Genzyme, Cambridge, MA) was used as standard. Units/ milliliter were defined as the reciprocal of supernatant dilution yielding half-maximal cytotoxicity. For specificity, 1 pg/mL of monoclonal antibody (MoAb) 9B9 (#l 141333; Boehringer Mannheim) or MoAb 19S2" were used to neutralize LT or TNF activity, respectively. Alternatively, TNF and LT were measured by commercially available ELISAs (R & D systems, Abingdon, UK). ELISA for soluble murine TNFRs. ELISA for murine sTNFR was performed as described earlier." Briefly, a 96-well immunomaxisorp plate (Nunc, Roskilde, Denmark) was coated with rabbit antisoluble murine TNF-RI or rabbit antisoluble murine TNF-R2 (SO pL). Unspecific binding was blocked with bovine serum albumin (BSA). After washings, 50 pL diluted serum sample (1:lO) was added to each well. A standard titration curve was obtained by making a serial dilution of a known sample of recombinant murine TNF-RI or TNF-R2, respectively. Subsequently, plates were washed and incubated with biotinylated polyclonal rabbit antisoluble mTNF-RI or rabbit antisoluble mTNF-R2. After washing, plates were incubated with streptavidin peroxidase followed by enzyme reaction. The detection limit for murine sTNF-RI is 5 pg/mL and for sTNF-R2 50 pg/mL. The sTNFR ELISA recognizes both unbound receptors and receptor-ligand complexes.
Animal studies. Six to eight-week old female BALB/c nu/nu and CB 17 SCID mice were obtained from Bomholtgard (Ry, Denmark) and maintained in pathogen-free conditions. Exponentially growing cells were harvested, washed, and injected either intraperitoneally (IP) or subcutaneously (SC) into the belly region of mice in a volume of 0.2 mL in D-PBS. Tumor size was measured in millimeters by using a caliper and was recorded as published." To attribute toxic effects described herein to the gene modified tumor cells, each experiment contained a group of animals from the same batch of mice that were observed throughout the experiment and shown to be phenotypically healthy.
RESULTS

Expression vectors were constructed containing human
T N F o r LT cDNA coding sequences under the control of either MoMuLV-LTR (pLTR-hTNF and pLTR-hLT) or chicken @actin promotors (pBA-hTNF and pBA-hLT) (Fig  1) A total of 5 X IO" CHO-TNF.2, CHO-LT.2 and CHOneo cells were injected (IP) into nude mice. As has been shown by Oliff et al,' mice injected with CHO-TNF.2 cells died more rapidly and at a higher percentage compared with those injected with control cells (Fig 2) . In contrast, CHO- were subsequently injected SC into SCID mice. We had previously learned that the antitumor activity of TNF was similar in nude and SCID mice" and that C H 0 cells grew more reliably as tumor in SCID compared with nude mice.*' The observation that xenogenic tumor grafts can grow better in SClD compared with nude mice has already been made by others.'" As shown in Fig 3A, C H 0 and CHO-neo cells grew progressively as tumor in SCID mice and all mice had to be killed by about 4 weeks. In contrast, tumor growth of CHO-TNF.2 and CHO-LT.2 cells was strongly suppressed in SClD mice and LT producing tumors remained consistently smaller than those producing TNF. In either case, this effect was indirect because proliferation of TNFlLT producing C H 0 cells was unchanged in vitro. Surprisingly, all mice (5 of 5) injected with CHO-TNF.2 cells died by day 16, when tumor load was very small, whereas CHO-LT.2 cell injected mice either survived long-term (3 of 5) with persistent small tumor nodule throughout the experiment (=2 months) or died much later (2 of 5 ) compared with the mice injected with CHO-TNF.2 cells. Similarly, in a second (and third, not shown) experiment, both TNF and LT suppressed tumor growth of the respective cells in comparison to mocktransfected C H 0 cells (Fig 3B) . Furthermore, mice injected with CHO-TNF.2 cells fall into two groups: they either died rapidly (2 of S mice), as observed in the first experiments without prior weight loss or progressively lost weight and died of cachexia (3 of 5 mice) (Fig 4) . In contrast, from the group of mice injected with CHO-LT.2 cells, the first mouse died at a time when the last mouse from the CHO-TNF.2 mice had died. They never died rapidly without prior weight loss, and weight loss started about 1 month later than observed in CHO-TNF.2 cell injected mice. To exclude clonal artefacts responsible for the above mentioned effects, several other clones producing either no or intermediate levels of TNFILT were analyzed in SCID mice. Noncytokine producing sublines grew in all cases similar to tumor as parental cells, and tumor growth of cells producing TNF or LT was reduced, albeit to a lower extent, than that of CHO-TNF.2 or CHO-LT.2 cells due to their lower TNF/LT production.
Because it has been previously shown that weight loss (cachexia) caused by TNF-producing tumors was associated with certain systemic TNF levels,' SCID mice were injected SC with CHO-TNF.2, CHO-LT.2, or CHO-neo cells to compare serum TNF and LT levels. Mice were killed at various time points after tumor size and weight of the animals had been determined (Table 2) . Average tumor size in the three groups of mice was as observed before, and mice injected with CHO-TNF.2, but not CHO-LT.2 or CHO-neo cells, had started to lose body weight, and some were already moribund or had died before. As determined by ELISA, mice injected 20 to 22 days before with CHO-TNF.2 cells, had serum TNF levels between 220 to 400 pg/mL. CHO-LT.2 cell injected animals contained serum levels of 320 to 2,500 p g / d LT 20 to 34 days after tumor cell injection. Five of eight mice had reached LT serum level of more than 1,000 pg/mL. However, they did not yet show symptoms of systemic toxicity. The cytokine gene modified CH0 cells continued to produce TNFILT in vivo, as each two 20-day old CHO-TNF.2 and CHO-LT.2 tumors were recultured, and in all four cases, the cells expressed approximately half of the original amount of TNFILT (Table 2) .
So far, the comparison of biologic effects of TNF and LT in vivo suggested that both molecules have similar local effects as shown by tumor suppression, but different systemic effects as demonstrated by toxicity in mice. To find an explanation for that, soluble TNF receptors were analyzed in the serum of SCID mice injected before with CHO-LT.2, CHO-TNF.2 and as control CHO-neo cells. In mice bearing CHO-neo tumors, serum soluble TNF-R1 levels were 0.3 2 0.07 ng/mL, which was similar to that of untreated mice (0.25 2 0.1 1 ng/mL) ( Table 3) . Lower levels were detected in SCID mice injected with CHO-TNF.2 (0.07 t 0.1 ng/ mL) or CHO-LT.2 cells (0.07 2 0.07 ng/mL). Soluble TNF-R2 was induced by CH0 cells in comparison with normal mice (13 2.2 v 3.3 t 1.4 ng/mL) . In mice bearing CHO-TNF.2 tumors, soluble TNF-R2 levels were increased (17.5 i-6.1 ng/mL), whereas they were decreased (9.0 i-1.4 ng/ mL) in sera from CHO-LT.2 pretreated mice 20 to 22 days after injection of the cells. Serum concentrations of soluble TNF-R2 were elevated in CHO-LT.2 cell injected mice when serum was taken after 34 days.
DISCUSSION
The therapeutic index of cytokines as anticancer agents may be defined by efficacy and toxicity. The aim of this study was to compare the therapeutic index of LT with that of TNF. For this purpose, expression of cytokine genes in tumor cells has been shown to be a valuable tool because local cytokine production at the site of tumor growth is most effective but least
In the current report, nude as well as SCID mice, were used as experimental animals, in which TNF and LT induce long-term suppression, but in most cases no complete tumor elimination due to the absence of func- For Table 2 . Abbreviation: ND, not done.
THE THERAPEUTIC INDEX OF LT COMPARED WITH TNF
Below the detection limit of the ELlSA (5 pg/mL).
tional T lymphocytes.22
This allowed us to analyze antitumor activity and systemic toxicity of these two related cytokines simultaneously in the same mice. Our results confirmed those observed by Oliff et a17 in that on IP injection into nude mice, CHO-TNF cells induced accelerated mortality of the mice (Fig 2) , whereas SC injection of CHO-TNF cells into nude mice led to diminished tumor growth in comparison with parental cells (data not shown). Because parental C H 0 cells at a dose of 5 X lo6 did not reproducibly grow in all of the nude mice, we have further analyzed biologic effects of CHO-TNF and CHO-LT cells in SCID mice, which are more permissive for tumor growth of SC injected C H 0 cells.23." In SCID mice, we made two observations: (1) TNFmediated toxicity manifested under conditions where tumor growth was effectively suppressed, and (2) part of the mice died rapidly without weight loss. At the present time, we have no explanation why the severeness of disease mediated by CHO-TNF cells varied within the same group of mice. The reason for the latter observation cannot be explained by different serum TNF levels ( Table 2 ). The strong synergy between TNF and bacterial products to cause lethal shock" would suggest the contribution of additional factor(s) in those CHO-TNF cell injected mice dying rapidly without prior weight loss. However, we could not detect any contami-2703 nation of CHO-TNF or CHO-LT cells by a number of infectious agents which were analyzed (see Materials and Methods), and we did not observe any symptoms of illness in repeated experiments in control mice. Our results showed a strong antitumor effect of LT in vivo. This may not be surprising because TNF and LT share many biologic properties. However, comparison of C H 0 cells producing very similar quantities of biologic active TNF or LT, respectively, showed several different in vivo biologic effects mediated by the two molecules: (1) LT producing tumors remained consistently smaller than those secreting TNF. In either case, inhibition of tumor growth was indirect because expression of TNF or LT did not change the growth rate of the cells in vitro. We have previously shown that TNF induced a rapid inflammatory response into TNF gene transfected tumors.4*22 The infiltrate contained a substantial number of macrophages, which were at least in part, responsible for the low tumorigenicity of TNF gene transfected tumor cells. Preliminary immunohistochemical analysis showed also a strong macrophage infiltration of both TNF and LT producing C H 0 tumors (data not shown). However, parental C H 0 tumors were also infiltred by a substantial number of rnacrophage~,~~ whose contribution (eg, in terms of tumoricidal activity in the C H 0 model) is not yet clear. Analysis of another LT gene transfected tumor cell line in a syngeneic mouse model showed that LT similar to TNF-producing tumor cells induce T cells dependent and independent effector mechanisms (manuscript in preparation). (2) Despite its potent antitumor effect, LT was clearly less toxic than TNF. This was most pronounced, with respect to induction of rapid death, without weight loss in SCID mice, which we never observed in repeated experiments with CHO-LT cells. Furthermore, LT mediated cachexia occurred about 1 month later compared with that induced by TNF. A reduced ability of LT to synergize with bacterial lipopolysaccharide (LPS) to mediate lethal shock has already been observed by Rothstein and Schreiber.'' In this regard, it is interesting to note that C H 0 cells transfected to produce TNF or LT constitutively produced interleukin-6 (L-6) activity in similar amounts (1 to 2 ng/mL), whereas parental or mock-transfected C H 0 cells expressed significantly less E -6 (0.4 ng/mL) (data not shown). Whether IL-6 is involved in the disparate systemic toxic effects of TNF and LT, is currently under investigation. (3) Higher serum levels of LT compared with TNF were tolerated by the mice without being toxic. A longer serum half-life of intravenously applied LT has been observed by others. However, toxicity has not been analyzed. 26 There is increasing evidence that beside a number of common characteristics, TNF and LT have a variety of disparate effects in vitro. Both quantitative and qualitative differences have been detected, and LT, in several functions, is less active than TNF.'4.27 The molecular basis for these differences is poorly understood, in particular, because both TNF and LT bind to the two common TNF receptors TNF-R1 and TNF-R2.28-33 In the mouse system, human TNF binds only to TNF-R1, but not TNF-R2.% Similarly, human LT also binds to murine TNF-R1, but not to TNF-R2 (D. to note that TNF and LT bioactivity produced by transfected CH0 cells were calibrated by cytotoxicity on mouse L929 cells, which occurs through the TNF-R1.35 Therefore, the finding that TNF and LT in one experimental system have both similar (local antitumor activity) and disparate (systemic toxicity) effects may have different explanations. The recent cloning of the LT-P gene, which is required to display LT on the cell surface, suggests that at least part of the function of LT resides in the membrane bound form.'6 However, C H 0 cells do not seem to express Alternatively, induction of receptor shedding may be different for TNF and LT in vivo. Both types of TNF receptors occur as soluble form in the serum and ~r i n e~~"~, '~ and are able to neutralize biologic activity of TNFILT. Lantz et have shown that LT is more potent than TNF in induction of TNF-R1 shedding from HL60 cells. Therefore, we analyzed soluble TNF receptors in sera of mice injected with CHO-TNF or CHO-LT cells. Soluble TNF-R1 levels were similarly reduced in sera of mice injected with LT or TNFproducing cells. In contrast, TNF led to an increase, and LT to a decrease, in soluble TNF-R2 serum levels compared with that induced by nontransfected C H 0 cells. Recently, Higuchi and A g g a r~a l~~
showed that binding of TNF to its receptors leads to a rapid internalization of TNF-R1 and shedding of TNF-R2, and that the signaling for both is mediated through the TNF-R1. An important role of TNF-R2 in inactivation and clearance of TNF by the kidney has been shown.40 Whether the different soluble TNF-R2 levels in CHO-TNF and CHO-LT treated mice are causually related to the lower toxicity of LT is not yet clear, in particular, because neither human TNF nor LT bind to mouse TNF-R2 (D. Goeddel, personal communication, October 1994). However, human TNF and LT may differently induce endogenous mouse TNF. It has been shown that administration of human TNF resulted in an increase of murine TNF of up to 1 r~g/mL.~' Although analyzed in a small number of mice, in one of three mice injected with CHO-TNF cells, but in none of four mice injected with CHO-LT cells, could we detect mouse TNF (data not shown). The precise mechanism, however, responsible for the lower systemic toxicity of LT compared with TNF has to be further analyzed.
To improve the therapeutic index, Van Ostade et all2 have engineered a human TNF molecule mutated for a single amino acid, which has lost binding to TNF-R2 and retained binding to the TNF-R1. By the analogy that human TNF binds only to the mouse TNF-R1 and is less toxic than murine TNF in mice, they concluded that this mutant TNF might still exert its direct antitumor effect, while inducing less systemic toxicity in humans. Our results suggest that LT represents a naturally evolved TNF molecule with high antitumor activity, but low toxicity.
